samedan logo
 
 
 
spacer
home > ebr > winter 2001 > the road ahead for drug delivery
PUBLICATIONS
European Biopharmaceutical Review

The Road Ahead for Drug Delivery

At the turn of the millennium pharmaceutical companies face two major problems. The patent protection for many established drugs is coming to an end and new biotechnology-derived products, namely peptides and proteins or even nucleic acids, are either metabolised when administered intravenously or broken down by the digestive system when delivered orally. Drug delivery is the field of research which promises to solve these challenges.In particular, the motivation for patent extension and product differentiation is the driving force of the market. Many companies are turning to drug delivery systems either to extend the lifetime of a brand product, or to produce a generic version with competitive edge. This leads to improved safety and efficacy as well as increased patient compliance, allowing patients to treat themselves. Drug delivery can, in some instances, resolve toxicological problems of drug candidates due to lower dosing and more precise application. Overall drug delivery can provide a significant competitive advantage for the drug company.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ulrich Gerth, Vice President of Equity Corporate Finance at HypoVereinsbank AG

Dr Ulrich C. Gerth is Vice President of Equity Corporate Finance at HypoVereinsbank. He joined the company in April 2000 as a Biotechnology Analyst. Ulrich's work covered the biotech sector, focusing particularly on technology, products and business models. He moved to the Corporate Finance department in July 2001.
Ulrich previously worked as a Consultant for Ernst & Young's life sciences team. He was responsible for the pre-IPO evaluations of German biotechnology companies, provided classical consultation, conducted market research and was a Co-Author of two of their European Life Sciences Reports. After gaining a degree in Biochemistry from the University of Witten/Herdecke, Ulrich obtained his doctorate degree in Molecular Medicine from Oxford University, UK. His work has been published in various science journals and he is currently training as a Certified European Financial Analyst (CEFA).

spacer
Dr Ulrich C. Gerth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myonex Opens New Global Headquarters

Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement